Sanofi and Regeneron's checkpoint inhibitor Libtayo has tripled its approved uses in Europe, after getting the nod for the treatment of advanced basal cell carcinoma (BCC) and advanced non-small ...

Cemiplimab gained its first US approval in 2018 for use in locally advanced or metastatic cutaneous squamous cell carcinoma. Like other ICIs, and unlike HHIs, cemiplimab seeks to restimulate the ...

Sanofi and Regeneron plan to file their cancer immunotherapy Libtayo (cemiplimab ... time a medicine has shown a clinical benefit in basal cell carcinoma patients who have progressed or are ...

Despite these challenges, Regeneron's other drugs, particularly Dupixent and Libtayo, show promise for ... 2012 to treat metastatic colorectal cancer (marketed as Zaltrap). Both were formed ...

The potential to challenge incumbents Keytruda and Libtayo in the cSCC space is ... in EXON 19 deletion non-small cell lung cancer (“NSCLC”), with a competitive safety profile.